A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens-Reference-Cited by-同舟云学术

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

Published:2006 Issue:2 Volume:106 Page:337-345
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wierda William,O'Brien Susan,Faderl Stefan,Ferrajoli Alessandra,Wang Xuemei,Do Kim-Anh,Garcia-Manero Guillermo,Thomas Deborah,Cortes Jorge,Ravandi-Kashani Farhad,Giles Francis,Lerner Susan,Kantarjian Hagop,Keating Michael

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference17 articles.

1. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

2. Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia

3. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

4. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

5. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors;BMC Cancer;2022-11-25

2. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study;The Lancet Oncology;2017-02

3. Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL;Acta Haematologica Polonica;2016-07

4. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis;Critical Reviews in Oncology/Hematology;2015-06

5. Rituximab (Rituxan®);Handbook of Therapeutic Antibodies;2014-08-12